NCT00242424View on ClinicalTrials.gov

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,375

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2007

Conditions
Inactivated Influenza Vaccine
Interventions
BIOLOGICAL

2005-2006 trivalent inactivated influenza vaccine

Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.

Trial Locations (1)

98105

Seattle Children's Hospital and Regional Medical Center, Seattle

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

Seattle Children's Hospital

OTHER

NCT00242424 - Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age | Biotech Hunter | Biotech Hunter